Fortress Biotech Pref Preferred Stock Performance
| FBIOP Preferred Stock | USD 6.63 0.11 1.63% |
Fortress Biotech has a performance score of 1 on a scale of 0 to 100. The firm shows a Beta (market volatility) of 0.18, which means not very significant fluctuations relative to the market. As returns on the market increase, Fortress Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Fortress Biotech is expected to be smaller as well. Fortress Biotech Pref right now shows a risk of 2.98%. Please confirm Fortress Biotech Pref value at risk, as well as the relationship between the skewness and day median price , to decide if Fortress Biotech Pref will be following its price patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Fortress Biotech Pref are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. Even with relatively invariable basic indicators, Fortress Biotech is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 235 M | |
| Total Cashflows From Investing Activities | 40.5 M |
Fortress |
Fortress Biotech Relative Risk vs. Return Landscape
If you would invest 660.00 in Fortress Biotech Pref on December 24, 2024 and sell it today you would earn a total of 3.00 from holding Fortress Biotech Pref or generate 0.45% return on investment over 90 days. Fortress Biotech Pref is currently producing 0.0494% returns and takes up 2.9773% volatility of returns over 90 trading days. Put another way, 26% of traded preferred stocks are less volatile than Fortress, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Fortress Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Fortress Biotech's investment risk. Standard deviation is the most common way to measure market volatility of preferred stocks, such as Fortress Biotech Pref, and traders can use it to determine the average amount a Fortress Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0166
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | FBIOP |
Estimated Market Risk
| 2.98 actual daily | 26 74% of assets are more volatile |
Expected Return
| 0.05 actual daily | 1 99% of assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average Fortress Biotech is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Fortress Biotech by adding it to a well-diversified portfolio.
Fortress Biotech Fundamentals Growth
Fortress Preferred Stock prices reflect investors' perceptions of the future prospects and financial health of Fortress Biotech, and Fortress Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Fortress Preferred Stock performance.
| Return On Equity | -1.43 | ||||
| Return On Asset | -0.35 | ||||
| Profit Margin | (1.17) % | ||||
| Operating Margin | (2.63) % | ||||
| Current Valuation | 2.58 B | ||||
| Shares Outstanding | 56.68 M | ||||
| Price To Sales | 1.36 X | ||||
| Revenue | 68.79 M | ||||
| EBITDA | (46.05 M) | ||||
| Cash And Equivalents | 248.77 M | ||||
| Cash Per Share | 2.31 X | ||||
| Total Debt | 46.56 M | ||||
| Debt To Equity | 0.81 % | ||||
| Book Value Per Share | 0.57 X | ||||
| Cash Flow From Operations | (116.54 M) | ||||
| Earnings Per Share | (0.86) X | ||||
| Total Asset | 396.5 M | ||||
About Fortress Biotech Performance
Assessing Fortress Biotech's fundamental ratios provides investors with valuable insights into Fortress Biotech's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Fortress Biotech is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York. Fortress Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 173 people.Things to note about Fortress Biotech Pref performance evaluation
Checking the ongoing alerts about Fortress Biotech for important developments is a great way to find new opportunities for your next move. Preferred Stock alerts and notifications screener for Fortress Biotech Pref help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Fortress Biotech has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 68.79 M. Net Loss for the year was (164.83 M) with loss before overhead, payroll, taxes, and interest of (85.66 M). | |
| Fortress Biotech Pref has accumulated about 248.77 M in cash with (116.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.31. |
- Analyzing Fortress Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Fortress Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Fortress Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Fortress Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Fortress Biotech's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Fortress Biotech's preferred stock. These opinions can provide insight into Fortress Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Fortress Preferred Stock Analysis
When running Fortress Biotech's price analysis, check to measure Fortress Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fortress Biotech is operating at the current time. Most of Fortress Biotech's value examination focuses on studying past and present price action to predict the probability of Fortress Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fortress Biotech's price. Additionally, you may evaluate how the addition of Fortress Biotech to your portfolios can decrease your overall portfolio volatility.